Small molecule, peptide, New Chemical Entity (NCE);
Mechanism of action: Inhibition of androgen activation of SRC kinase
Primary Indication: Prostate cancer;
Follow-up Indications: Other hormone associated solid tumours such as Breast and Ovarian cancer
Licensed from: Cancer Research Technology (CRT) a part of CRUK
Published research: Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth. Migliaccio A, Varricchio L, De Falco A, Castoria G, Arra C, Yamaguchi H, Ciociola A, Lombardi M, Di Stasio R, Barbieri A, Baldi A, Barone MV, Appella E, Auricchio F (2007) Oncogene. 2007 Oct 11;26(46):6619-29.
Patents: PCT patent family applications WO/2008/113770; WO/2014/177868.
Granted and allowed patents: AU2008228274; EP2139917; JP5998161; JP6456922; JP6545122; JP6689430; US9919023; US10400008; further patents pending.